Syndax Pharmaceuticals/$SNDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Ticker
$SNDX
Sector
Primary listing
Employees
270
Headquarters
Website
SNDX Metrics
BasicAdvanced
$1.1B
-
-$3.89
0.73
-
Price and volume
Market cap
$1.1B
Beta
0.73
52-week high
$21.55
52-week low
$8.58
Average daily volume
2.8M
Financial strength
Current ratio
4.706
Quick ratio
4.48
Long term debt to equity
206.918
Total debt to equity
219.486
Interest coverage (TTM)
-16.35%
Profitability
EBITDA (TTM)
-339.046
Gross margin (TTM)
-237.92%
Net profit margin (TTM)
-429.84%
Operating margin (TTM)
-435.06%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-39.49%
Return on equity (TTM)
-113.22%
Valuation
Price to revenue (TTM)
14.489
Price to book
7.17
Price to tangible book (TTM)
7.17
Price to free cash flow (TTM)
-3.731
Free cash flow yield (TTM)
-26.81%
Free cash flow per share (TTM)
-3.514
Growth
Revenue change (TTM)
2,126.66%
Earnings per share change (TTM)
14.98%
3-year revenue growth (CAGR)
-17.53%
10-year revenue growth (CAGR)
132.34%
3-year earnings per share growth (CAGR)
637.63%
10-year earnings per share growth (CAGR)
-41.99%
What the Analysts think about SNDX
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
Bulls say / Bears say
Revuforj net product revenue reached $28.6 million in Q2 2025, a 43% increase from the previous quarter, showing strong commercial uptake since launch.
The FDA granted Priority Review for the supplemental NDA for revumenib in relapsed/refractory mNPM1 AML, setting a PDUFA action date of October 25, 2025—creating a near-term regulatory catalyst.
In the BEAT AML trial, revumenib combined with venetoclax and azacitidine achieved a 100% overall response rate and a 95% composite complete remission rate in newly diagnosed mNPM1 and KMT2Ar AML patients, demonstrating impressive efficacy.
Syndax posted a net loss of $71.8 million for Q2 2025 and burned through about $84 million in cash, bringing cash and investments down to $517.9 million, which could strain its financial runway if growth slows.
R&D expenses for Q2 2025 were $62.2 million and SG&A expenses were $43.8 million, totaling $106 million—more than double the quarter's revenue—highlighting significant operating leverage risk.
Revuforj treatment shows a 29% rate of differentiation syndrome, including fatal outcomes, posing serious safety and tolerability issues.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
SNDX Financial Performance
Revenues and expenses
SNDX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Syndax Pharmaceuticals stock?
Syndax Pharmaceuticals (SNDX) has a market cap of $1.1B as of October 28, 2025.
What is the P/E ratio for Syndax Pharmaceuticals stock?
The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of October 28, 2025.
Does Syndax Pharmaceuticals stock pay dividends?
No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Syndax Pharmaceuticals dividend payment date?
Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.